Cargando…

MYCN protein stability is a better prognostic indicator in neuroblastoma

OBJECTIVE: MYCN oncogene amplification is associated with treatment failure and poor prognosis in neuroblastoma. To date, most detection methods of MYCN focus on DNA copy numbers instead of protein expression, which is the real one performing biological function, for poor antibodies. The current inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yi, Zhao, Jie, Zhang, Yingwen, Feng, Tianyue, Yv, Bo, Wang, Jing, Gao, Yijin, Yin, Minzhi, Tang, Jingyan, Li, Yanxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277955/
https://www.ncbi.nlm.nih.gov/pubmed/35820898
http://dx.doi.org/10.1186/s12887-022-03449-1
_version_ 1784746095222456320
author Yang, Yi
Zhao, Jie
Zhang, Yingwen
Feng, Tianyue
Yv, Bo
Wang, Jing
Gao, Yijin
Yin, Minzhi
Tang, Jingyan
Li, Yanxin
author_facet Yang, Yi
Zhao, Jie
Zhang, Yingwen
Feng, Tianyue
Yv, Bo
Wang, Jing
Gao, Yijin
Yin, Minzhi
Tang, Jingyan
Li, Yanxin
author_sort Yang, Yi
collection PubMed
description OBJECTIVE: MYCN oncogene amplification is associated with treatment failure and poor prognosis in neuroblastoma. To date, most detection methods of MYCN focus on DNA copy numbers instead of protein expression, which is the real one performing biological function, for poor antibodies. The current investigation was to explore a fast and reliable way to detect MYCN protein expression and evaluate its performance in predicting prognosis. METHODS: Several MYCN antibodies were used to detect MYCN protein expression by immunohistochemistry (IHC), and one was chosen for further study. We correlated the IHC results of MYCN from 53 patients with MYCN fluorescence in situ hybridization (FISH) and identified the sensitivity and specificity of IHC. The relationship between patient prognosis and MYCN protein expression was detected from this foundation. RESULTS: MYCN amplification status detected by FISH was most valuable for INSS stage 3 patients. In the cohort of 53 samples, IHC test demonstrated 80.0–85.7% concordance with FISH results. Further analyzing those cases with inconsistent results, we found that patients with MYCN amplification but low protein expression tumors always had a favorable prognosis. In contrast, if patients with MYCN non-amplified tumors were positive for MYCN protein, they had a poor prognosis. CONCLUSION: MYCN protein level is better than MYCN amplification status in predicting the prognosis of neuroblastoma patients. Joint of FISH and IHC could confirm MYCN protein stability and achieve better prediction effect than the singular method. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12887-022-03449-1.
format Online
Article
Text
id pubmed-9277955
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92779552022-07-14 MYCN protein stability is a better prognostic indicator in neuroblastoma Yang, Yi Zhao, Jie Zhang, Yingwen Feng, Tianyue Yv, Bo Wang, Jing Gao, Yijin Yin, Minzhi Tang, Jingyan Li, Yanxin BMC Pediatr Research OBJECTIVE: MYCN oncogene amplification is associated with treatment failure and poor prognosis in neuroblastoma. To date, most detection methods of MYCN focus on DNA copy numbers instead of protein expression, which is the real one performing biological function, for poor antibodies. The current investigation was to explore a fast and reliable way to detect MYCN protein expression and evaluate its performance in predicting prognosis. METHODS: Several MYCN antibodies were used to detect MYCN protein expression by immunohistochemistry (IHC), and one was chosen for further study. We correlated the IHC results of MYCN from 53 patients with MYCN fluorescence in situ hybridization (FISH) and identified the sensitivity and specificity of IHC. The relationship between patient prognosis and MYCN protein expression was detected from this foundation. RESULTS: MYCN amplification status detected by FISH was most valuable for INSS stage 3 patients. In the cohort of 53 samples, IHC test demonstrated 80.0–85.7% concordance with FISH results. Further analyzing those cases with inconsistent results, we found that patients with MYCN amplification but low protein expression tumors always had a favorable prognosis. In contrast, if patients with MYCN non-amplified tumors were positive for MYCN protein, they had a poor prognosis. CONCLUSION: MYCN protein level is better than MYCN amplification status in predicting the prognosis of neuroblastoma patients. Joint of FISH and IHC could confirm MYCN protein stability and achieve better prediction effect than the singular method. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12887-022-03449-1. BioMed Central 2022-07-11 /pmc/articles/PMC9277955/ /pubmed/35820898 http://dx.doi.org/10.1186/s12887-022-03449-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yang, Yi
Zhao, Jie
Zhang, Yingwen
Feng, Tianyue
Yv, Bo
Wang, Jing
Gao, Yijin
Yin, Minzhi
Tang, Jingyan
Li, Yanxin
MYCN protein stability is a better prognostic indicator in neuroblastoma
title MYCN protein stability is a better prognostic indicator in neuroblastoma
title_full MYCN protein stability is a better prognostic indicator in neuroblastoma
title_fullStr MYCN protein stability is a better prognostic indicator in neuroblastoma
title_full_unstemmed MYCN protein stability is a better prognostic indicator in neuroblastoma
title_short MYCN protein stability is a better prognostic indicator in neuroblastoma
title_sort mycn protein stability is a better prognostic indicator in neuroblastoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277955/
https://www.ncbi.nlm.nih.gov/pubmed/35820898
http://dx.doi.org/10.1186/s12887-022-03449-1
work_keys_str_mv AT yangyi mycnproteinstabilityisabetterprognosticindicatorinneuroblastoma
AT zhaojie mycnproteinstabilityisabetterprognosticindicatorinneuroblastoma
AT zhangyingwen mycnproteinstabilityisabetterprognosticindicatorinneuroblastoma
AT fengtianyue mycnproteinstabilityisabetterprognosticindicatorinneuroblastoma
AT yvbo mycnproteinstabilityisabetterprognosticindicatorinneuroblastoma
AT wangjing mycnproteinstabilityisabetterprognosticindicatorinneuroblastoma
AT gaoyijin mycnproteinstabilityisabetterprognosticindicatorinneuroblastoma
AT yinminzhi mycnproteinstabilityisabetterprognosticindicatorinneuroblastoma
AT tangjingyan mycnproteinstabilityisabetterprognosticindicatorinneuroblastoma
AT liyanxin mycnproteinstabilityisabetterprognosticindicatorinneuroblastoma